论文部分内容阅读
目的:观察舒利迭吸入治疗COPD稳定期患者的疗效。方法:选取2007-2010年收治的60例慢性阻塞性肺疾病(COPD)稳定期患者随机分为治疗组和对照组各30例,两组均予COPD常规治疗,在此基础上治疗组给予舒利迭吸入,每次喷1下,2次/d;对照组口服茶碱缓释片,每次0.1g,2次/d,并酌情予沙丁胺醇(万托林)气雾剂,疗程均为12周。观察两组治疗前后肺功能、血气指标及不良反应情况。结果:治疗后治疗组肺功能、血气指标改善情况均明显优于对照组(P<0.01),不良反应少。结论:舒利迭吸入能明显改善COPD稳定期患者的肺功能及血气指标。
Objective: To observe the efficacy of seretide inhalation in patients with stable COPD. Methods: Sixty COPD patients with stable COPD from 2007 to 2010 were randomly divided into treatment group (30 cases) and control group (30 cases). Both groups were given routine treatment of COPD. On the basis of this, Instillation, each time spray 1, 2 times / d; control group oral theophylline sustained-release tablets, each 0.1g, 2 times / d, and as appropriate, to salbutamol 12 weeks. The two groups were observed before and after treatment of lung function, blood gas indicators and adverse reactions. Results: After treatment, the improvement of pulmonary function and blood gas indexes in the treatment group were significantly better than those in the control group (P <0.01), with fewer adverse reactions. Conclusion: Seretide inhalation can significantly improve pulmonary function and blood gas index in patients with stable COPD.